These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9385485)

  • 1. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S; Swarz H; Breisch SA; Maroli AN
    Clin Ther; 1997; 19(5):975-88. PubMed ID: 9385485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B; Dutchman DA; Pettit R; Maroli A
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
    Chodosh S; Lakshminarayan S; Swarz H; Breisch S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):114-20. PubMed ID: 9449270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
    Moola S; Hagberg L; Churchyard GA; Dylewski JS; Sedani S; Staley H
    Chest; 1999 Oct; 116(4):974-83. PubMed ID: 10531162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    DeAbate CA; Bettis R; Munk ZM; Fleming H; Munn NJ; Riffer E; Bagby B; Giguere G; Collins JJ
    Clin Ther; 1999 Jan; 21(1):172-88. PubMed ID: 10090434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE; Cranfield R; Breisch S; Pettit R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():63-72. PubMed ID: 9484875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE; Zuck P; Vogel F; McIvor A; Peirzchala W; Smakal M; Staley H; Marr C
    J Antimicrob Chemother; 1999 Oct; 44(4):515-23. PubMed ID: 10588313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 10. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
    Hoeffken G; Meyer HP; Winter J; Verhoef L;
    Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
    Geddes AM
    Expert Opin Investig Drugs; 1999 Apr; 8(4):487-505. PubMed ID: 15992094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of grepafloxacin compared with other fluoroquinolones.
    Stahlmann R; Schwabe R
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():83-92. PubMed ID: 9484877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of grepafloxacin against respiratory pathogens in the UK.
    Wise R; Andrews JM
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
    Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
    Fogarty CM; Patel TC; Dunbar LM; Leroy BP
    BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
    J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.